Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term safety and tolerability of LOU064 in chronic spontaneous urticaria (extension of CLOU064A2201)
jRCT2031210538Completed
- Sponsor
- Novartis
- Start
- Oct 2019
- Modality
- Small Molecules
01
Overview
Open-label trial of remibrutinib in chronic idiopathic urticaria (CIU) (2 arms), sponsored by Novartis. Primary endpoint: Long-term safety and tolerability of LOU064. Started Oct 2019; status: completed.
02
Drugs
remibrutinib
03
Conditions
chronic idiopathic urticaria (CIU)
Beyond the preview
Go deeper on jRCT2031210538.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031210538.